tetano
Editor, Senior Moderator
Infect Chemother. 2018 Feb 24. pii: S1341-321X(18)30032-1. doi: 10.1016/j.jiac.2018.01.013. [Epub ahead of print] [h=1]Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.[/h] Ishiguro N[SUP]1[/SUP], Koseki N[SUP]2[/SUP], Kaiho M[SUP]3[/SUP], Ariga T[SUP]3[/SUP], Kikuta H[SUP]4[/SUP], Oba K[SUP]5[/SUP], Togashi T[SUP]6[/SUP], Morita K[SUP]7[/SUP], Inagawa A[SUP]8[/SUP], Okamura A[SUP]9[/SUP], Yamazaki S[SUP]10[/SUP], Shida S[SUP]11[/SUP], Konno M[SUP]12[/SUP], Kawamura N[SUP]13[/SUP], Ishizaka A[SUP]14[/SUP], Takada K[SUP]15[/SUP], Tsubakihara K[SUP]16[/SUP], Nagano N[SUP]17[/SUP], Shibata M[SUP]18[/SUP], Furuyama H[SUP]19[/SUP], Matsuzono Y[SUP]20[/SUP], Koike A[SUP]21[/SUP], Murashita M[SUP]22[/SUP], Hatae Y[SUP]23[/SUP], Arioka H[SUP]24[/SUP], Yamanaka T[SUP]25[/SUP], Watanabe T[SUP]26[/SUP], Tabata Y[SUP]27[/SUP], Kumita Y[SUP]28[/SUP], Hazama K[SUP]29[/SUP], Akutsu Y[SUP]30[/SUP], Aoyagi H[SUP]31[/SUP], Tobise C[SUP]32[/SUP], Azuma K[SUP]33[/SUP], Yasoshima K[SUP]34[/SUP], Sawada Y[SUP]35[/SUP], Uetsuji K[SUP]36[/SUP], Tsuchida A[SUP]37[/SUP], Tsuchiyama A[SUP]38[/SUP], Yasuda K[SUP]39[/SUP], Odagawa Y[SUP]40[/SUP], Yoshioka M[SUP]41[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A- or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A- or B-infected patients aged 5-9 years was 2.13-times greater than that in patients aged 10-18 years (p = 0.012).
[h=4]KEYWORDS:[/h] Influenza A; Influenza B; Laninamivir; Oseltamivir; Peramivir; Zanamivir
PMID: 29487035 DOI: 10.1016/j.jiac.2018.01.013
[h=3]Author information[/h]
[h=3]Abstract[/h] The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A- or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A- or B-infected patients aged 5-9 years was 2.13-times greater than that in patients aged 10-18 years (p = 0.012).
[h=4]KEYWORDS:[/h] Influenza A; Influenza B; Laninamivir; Oseltamivir; Peramivir; Zanamivir
PMID: 29487035 DOI: 10.1016/j.jiac.2018.01.013